menu
    • menu
    [{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"mRNA-6231","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Moderna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"CB1 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enzo Biochem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"SK1-I","moa":"Sphingosine Kinase 1","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzo Biochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Enzo Biochem \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzo Biochem \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Small molecule","date":"March 2020","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Biotechnology Value Fund"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"April 2020","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis"},{"orgOrder":0,"company":"Immutep","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"IMP761","moa":"LAG-3","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Immutep \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ Not Applicable"},{"orgOrder":0,"company":"ProThera Biologics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Plasma-derived Inter-alpha Inhibitor Proteins therapy","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ProThera Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ProThera Biologics \/ Takeda ","highestDevelopmentStatusID":"4","companyTruncated":"ProThera Biologics \/ Takeda "},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Anandamide","moa":"Complement C3","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TXR-711","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Mosedipimod","moa":"TLR4","graph1":"Immunology","graph2":"Preclinical","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enzychem Lifesciences Corporation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Enzychem Lifesciences Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Commonwealth of Pennsylvania","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Funding","leadProduct":"ST266","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Commonwealth of Pennsylvania"},{"orgOrder":0,"company":"Singota Solutions","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Collaboration","leadProduct":"ST266","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Singota Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Singota Solutions \/ Noveome Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Singota Solutions \/ Noveome Biotherapeutics"},{"orgOrder":0,"company":"Cellect Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2020","year":"2020","type":"Agreement","leadProduct":"ApoGraft treated stem cells","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellect Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cellect Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellect Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SYN-020","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Massachusetts General Hospital \/ Synthetic Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Massachusetts General Hospital \/ Synthetic Biologics"},{"orgOrder":0,"company":"Theraly Fibrosis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TLY012","moa":"DR5","graph1":"Immunology","graph2":"Preclinical","graph3":"Theraly Fibrosis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Theraly Fibrosis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Theraly Fibrosis \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"ALPN-30x","moa":"BAFF","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"3P Biopharmaceuticals","sponsor":"Toleranzia","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"TOL2","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"3P Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"3P Biopharmaceuticals \/ Toleranzia","highestDevelopmentStatusID":"4","companyTruncated":"3P Biopharmaceuticals \/ Toleranzia"},{"orgOrder":0,"company":"Melior Discovery","sponsor":"SFA Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"SFA005","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Melior Discovery \/ SFA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Melior Discovery \/ SFA Therapeutics"},{"orgOrder":0,"company":"ILIAS Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"ILB-202","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ILIAS Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ILIAS Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"ILIAS Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2020","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"","sponsorNew":"Citryll \/ BOM Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ BOM Brabant Ventures"},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"SDC-1802","moa":"JAK1\/TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Not Applicable"},{"orgOrder":0,"company":"Galmed Pharmaceuticals","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Amilo-5MER","moa":"Serum Amyloid A","graph1":"Immunology","graph2":"Preclinical","graph3":"Galmed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Galmed Pharmaceuticals \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Galmed Pharmaceuticals \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"VB-601","moa":"MOSPD2","graph1":"Immunology","graph2":"Preclinical","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VBL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VBL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Funding","leadProduct":"Tolimidone","moa":"Lyn kinase","graph1":"Immunology","graph2":"Preclinical","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines","highestDevelopmentStatusID":"4","companyTruncated":"Melior Pharmaceuticals \/ Commonwealth of Pennsylvania\u2019s COVID-19 Vaccines"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Vaccine","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"CEL-4000","moa":"Il-17 alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"CEL-SCI \/ National Institute of Health"},{"orgOrder":0,"company":"Creative Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ImmCelz","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Creative Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Creative Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical \/ Not Applicable"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosciences \/ Selecta Biosciences"},{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Piroxicam","moa":"COX","graph1":"Immunology","graph2":"Preclinical","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Nanoform \/ Quotient Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nanoform \/ Quotient Sciences"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydroxyl dendrimer","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ashvattha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"OSE-230","moa":"ChemR23","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-005 Z-PODS","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"ISD Immunotech","sponsor":"Biogen","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"ISD-017","moa":"STING pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"ISD Immunotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ISD Immunotech \/ Biogen Inc","highestDevelopmentStatusID":"4","companyTruncated":"ISD Immunotech \/ Biogen Inc"},{"orgOrder":0,"company":"BioInvent","sponsor":"Cantargia AB","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"November 2020","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1RAP","graph1":"Immunology","graph2":"Preclinical","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BioInvent \/ Cantargia","highestDevelopmentStatusID":"4","companyTruncated":"BioInvent \/ Cantargia"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-005 Z-PODS","moa":"Calcineurin","graph1":"Immunology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchison China MediTech","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Inmagene","highestDevelopmentStatusID":"4","companyTruncated":"Hutchison China MediTech \/ Inmagene"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Standigm","sponsor":"SK Chemicals","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Standigm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Standigm \/ SK Chemicals","highestDevelopmentStatusID":"4","companyTruncated":"Standigm \/ SK Chemicals"},{"orgOrder":0,"company":"Sareum","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"SDC-1802","moa":"TYK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sareum \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sareum \/ Not Applicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"ST266","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Noveome Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Noveome Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Slate Bio","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2021","year":"2021","type":"Financing","leadProduct":"IL233","moa":"IL-2","graph1":"Immunology","graph2":"Preclinical","graph3":"Slate Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Slate Bio \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Slate Bio \/ Epidarex Capital"},{"orgOrder":0,"company":"The Wistar Institute","sponsor":"Jubilant Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"The Wistar Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"The Wistar Institute \/ Jubilant Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"The Wistar Institute \/ Jubilant Therapeutics"},{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"injection","sponsorNew":"Imcyse \/ Pfizer","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ Pfizer"},{"orgOrder":0,"company":"Pandion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"PT001","moa":"PD-L1","graph1":"Immunology","graph2":"Preclinical","graph3":"Pandion Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhaler","sponsorNew":"Pandion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pandion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"iPSC-Derived Cell Therapies","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Fujifilm holding \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm holding \/ Sana Biotechnology"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Pandion Therapeutics"},{"orgOrder":0,"company":"Rodeo Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"$55.0 million","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"15-PGDH","graph1":"Immunology","graph2":"Preclinical","graph3":"Rodeo Therapeutics","amount2":0.71999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.71999999999999997,"dosageForm":"Oral","sponsorNew":"Rodeo Therapeutics \/ Amgen","highestDevelopmentStatusID":"4","companyTruncated":"Rodeo Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Argenx","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Efgartigimod","moa":"IgG-mediated immune response","graph1":"Immunology","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ argenx BV","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ argenx BV"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2021","year":"2021","type":"Funding","leadProduct":"OCi mAb","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"ImmunOs Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"ImmunOs Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"ImmunOs Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Immunology","graph2":"Preclinical","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MetrioPharm \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MetrioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Yale University","sponsor":"Aptorum","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Yale University \/ Aptorum","highestDevelopmentStatusID":"4","companyTruncated":"Yale University \/ Aptorum"},{"orgOrder":0,"company":"Interline Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"May 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Interline Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Interline Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"4","companyTruncated":"Interline Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Autobahn Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"ABX-003","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Autobahn Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Astellas Pharma \/ Autobahn Therapeutics"},{"orgOrder":0,"company":"Equillium","sponsor":"University of Oxford","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Itolizumab","moa":"CD6-ALCAM signaling pathway","graph1":"Immunology","graph2":"Preclinical","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Oxford University","highestDevelopmentStatusID":"4","companyTruncated":"Equillium \/ Oxford University"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"ALPN-303","moa":"B Cell cytokine","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"aNRP2-14","moa":"Sema3F\/NRP2","graph1":"Immunology","graph2":"Preclinical","graph3":"aTyr Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"aTyr Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"aTyr Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Apollo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Apollo Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"4","companyTruncated":"Apollo Therapeutics \/ Patient Square Capital"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Series A Financing","leadProduct":"Autologous Treg Cell Therapies","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Abata Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Abata Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Abata Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","upfrontCash":"$12.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"F-star Therapeutics","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.31,"dosageForm":"","sponsorNew":"F-star Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"F-star Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"AX-158","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artax Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Artax Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"CB 4332","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Catalyst Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"GentiBio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Forge Biologics \/ GentiBio","highestDevelopmentStatusID":"4","companyTruncated":"Forge Biologics \/ GentiBio"},{"orgOrder":0,"company":"Nutrapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Peptide","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"RPI-78M","moa":"Ach receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Nutrapharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Nutrapharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nutrapharma \/ Not Applicable"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cyrus Biotechnology \/ Selecta Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Selecta Bioscience"},{"orgOrder":0,"company":"AFYX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Anti-TNF\u03b1 Antibody","moa":"TNF alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"AFYX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"AFYX Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AFYX Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Preclinical","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medsenic \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Medsenic \/ Not Applicable"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Viva BioInnovator","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Viva BioInnovator","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Viva BioInnovator"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"EDP1867","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Evelo Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Neutralizing antibodies","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ Selecta Biosciences"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"IMG-007","moa":"OX40","graph1":"Immunology","graph2":"Preclinical","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Inmagene Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Inmagene Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"VENT-01","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ventus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$25.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Protein-based Therapeutics","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alpine Immune Sciences","amount2":1.5600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.5600000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Alpine Immune Sciences \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Alpine Immune Sciences \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2021","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG-3","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Immutep"},{"orgOrder":0,"company":"Chord Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Cladribine","moa":"DNA polymerase","graph1":"Immunology","graph2":"Preclinical","graph3":"Chord Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chord Therapeutics \/ Merck","highestDevelopmentStatusID":"4","companyTruncated":"Chord Therapeutics \/ Merck"},{"orgOrder":0,"company":"Amagma Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Amagma Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Amagma Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amagma Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","upfrontCash":"$8.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Xbrane Biopharma \/ Biogen Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen Inc."},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"SoftBank Vision Fund 2","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"February 2022","year":"2022","type":"Series C Financing","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ SoftBank Vision Fund 2","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ SoftBank Vision Fund 2"},{"orgOrder":0,"company":"Alvotech","sponsor":"Fuji Pharma","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Partnership","leadProduct":"AVT16","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ Fuji Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Alvotech \/ Fuji Pharma"},{"orgOrder":0,"company":"Orange Grove Bio","sponsor":"Cincinnati Children\u2019s Hospital Medical Center","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Orange Grove Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"Orange Grove Bio \/ Cincinnati Children\u2019s Hospital Medical Center"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"VYN201","moa":"BET","graph1":"Immunology","graph2":"Preclinical","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Immunology","graph2":"Preclinical","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"KT-474","moa":"STAT3 protein","graph1":"Immunology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enosi Therapeutics","sponsor":"Danuo Science Group","pharmaFlowCategory":"D","upfrontCash":"$5.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"EN1001","moa":"TNFR1","graph1":"Immunology","graph2":"Preclinical","graph3":"Enosi Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"","sponsorNew":"Enosi Therapeutics \/ Danuo Science Group","highestDevelopmentStatusID":"4","companyTruncated":"Enosi Therapeutics \/ Danuo Science Group"},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-100","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Aditxt \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Not Applicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"AM-411","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Curia","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"srRNA Therapeutic","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Curia \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Curia \/ Replicate Bioscience"},{"orgOrder":0,"company":"Trethera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"TNX-1500","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"CUE-401","moa":"IL-2","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Aditxt","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Plasmid DNA-based Therapeutic","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Aditxt","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Aditxt \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lactiga","sponsor":"1517 Fund","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Financing","leadProduct":"LCTG-001","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Lactiga","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Lactiga \/ 1517 Fund","highestDevelopmentStatusID":"4","companyTruncated":"Lactiga \/ 1517 Fund"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Fc-modified Anti-CD154mAb","moa":"CD154","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"HL161ANS","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"CABA-201","moa":"CD19","graph1":"Immunology","graph2":"Preclinical","graph3":"IASO Bio","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"","sponsorNew":"IASO Bio \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"IASO Bio \/ Cabaletta Bio"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"CAN106","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"CANbridge Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ribon Therapeutics \/ Boehringer Ingelheim","highestDevelopmentStatusID":"4","companyTruncated":"Ribon Therapeutics \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Collaboration","leadProduct":"TNX-1500","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Boston Children's Hospital"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"NEO-TRA1","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Neoleukin Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Neoleukin Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"University of Maryland","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Silo Pharma \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ University of Maryland"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.66000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.66000000000000003,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Gilead","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Gilead"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"VENT-03","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"eGenesis","sponsor":"Eledon Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Tegoprubart","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"eGenesis \/ Eledon Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"eGenesis \/ Eledon Pharmaceuticals"},{"orgOrder":0,"company":"Evoq Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","date":"January 2023","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Evoq Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Evoq Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"4","companyTruncated":"Evoq Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Maryland","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Agreement","leadProduct":"TNX-1500","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Maryland"},{"orgOrder":0,"company":"IgGenix","sponsor":"Alexandria Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"IgGenix \/ Alexandria Venture","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Alexandria Venture"},{"orgOrder":0,"company":"Biora Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biora Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biora Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biora Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"CUE-401","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Cue Biopharma","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.22,"dosageForm":"","sponsorNew":"Cue Biopharma \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Cue Biopharma \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"Pillar VC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2023","year":"2023","type":"Financing","leadProduct":"THY-100","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"","sponsorNew":"Thymmune Therapeutics \/ Pillar VC","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ Pillar VC"},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Allergen-specific Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"IgGenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Not Applicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"JBI-589","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Jubilant Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Jubilant Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ossium Health","sponsor":"California Institute of Regenerative Medicine","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"April 2023","year":"2023","type":"Funding","leadProduct":"OSSM-007","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Ossium Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Ossium Health \/ California Institute of Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ossium Health \/ California Institute of Regenerative Medicine"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"MRT-6160","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Monte Rosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Monte Rosa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Monte Rosa Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Exo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Exo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Exo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Charles River Laboratories","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"IMP761","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immutep \/ Charles River Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Immutep \/ Charles River Laboratories"},{"orgOrder":0,"company":"Celltrion","sponsor":"Rani Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"June 2023","year":"2023","type":"Partnership","leadProduct":"Adalimumab","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celltrion \/ Rani Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Celltrion \/ Rani Therapeutics"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Funding","leadProduct":"HY-083","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hyloris Pharmaceuticals \/ Walloon Region","highestDevelopmentStatusID":"4","companyTruncated":"Hyloris Pharmaceuticals \/ Walloon Region"},{"orgOrder":0,"company":"Recludix Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Recludix Pharma","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Recludix Pharma \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Recludix Pharma \/ Sanofi"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Alger","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Financing","leadProduct":"FB-102","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Forte Biosciences \/ Alger","highestDevelopmentStatusID":"4","companyTruncated":"Forte Biosciences \/ Alger"},{"orgOrder":0,"company":"Trethera","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Trethera \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Trethera \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Mysthera Therapeutics","sponsor":"Forty51 Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Mysthera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mysthera Therapeutics \/ Forty51 Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Mysthera Therapeutics \/ Forty51 Ventures"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Cabaletta Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"August 2023","year":"2023","type":"Agreement","leadProduct":"CABA-201","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Advanced Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"WuXi Advanced Therapies \/ Cabaletta Bio","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Advanced Therapies \/ Cabaletta Bio"},{"orgOrder":0,"company":"BITT","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"August 2023","year":"2023","type":"Funding","leadProduct":"BITT-101","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"BITT","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"BITT \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"BITT \/ National Institutes of Health"},{"orgOrder":0,"company":"IMIDomics","sponsor":"TNAX Biopharma Corporation","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"TNAX101A","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ TNAX Biopharma Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ TNAX Biopharma Corporation"},{"orgOrder":0,"company":"Thymmune Therapeutics","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"September 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Thymmune Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Thymmune Therapeutics \/ U.S. Department of Health and Human Services","highestDevelopmentStatusID":"4","companyTruncated":"Thymmune Therapeutics \/ U.S. Department of Health and Human Services"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"IMIDomics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"TNAX101A","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ IMIDomics","highestDevelopmentStatusID":"4","companyTruncated":"WuXi Biologics \/ IMIDomics"},{"orgOrder":0,"company":"IMIDomics","sponsor":"University of Barcelona","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"IMB-1003","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ University of Barcelona","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ University of Barcelona"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Ingenia Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ INGENIA Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Nona Biosciences \/ INGENIA Therapeutics"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Odyssey Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"December 2023","year":"2023","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Odyssey Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Odyssey Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"4","companyTruncated":"Odyssey Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"BTIG, LLC","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Private Placement","leadProduct":"COYA-201","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Coya Therapeutics \/ BTIG, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ BTIG, LLC"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$7.5 million","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"January 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"January 2024","year":"2024","type":"Agreement","leadProduct":"Arsenic Trioxide","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Phebra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Phebra \/ BioSenic","highestDevelopmentStatusID":"4","companyTruncated":"Phebra \/ BioSenic"},{"orgOrder":0,"company":"Synthekine","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$40.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Synthekine \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Synthekine \/ Sanofi"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$17.5 million","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Precision BioSciences \/ TG Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ TG Therapeutics"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$48.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Partnership","leadProduct":"OSE-230","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"March 2024","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"IMIDomics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"March 2024","year":"2024","type":"Financing","leadProduct":"IMB1001","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IMIDomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"IMIDomics \/ UCB Pharma S.A","highestDevelopmentStatusID":"4","companyTruncated":"IMIDomics \/ UCB Pharma S.A"},{"orgOrder":0,"company":"UNeMed","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"COYA 301","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"UNeMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UNeMed \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"UNeMed \/ Coya Therapeutics"},{"orgOrder":0,"company":"IFM Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","upfrontCash":"$90.0 million","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IFM Therapeutics","amount2":0.83999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.83999999999999997,"dosageForm":"","sponsorNew":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"IFM Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"IgGenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"IGNX001","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IgGenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"IgGenix \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"IgGenix \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"NX-0479","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Nurix Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nurix Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"CNTY-101","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Century Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Century Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Century Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$48.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"OSE-230","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"OSE Immunotherapeutics SA","amount2":0.70999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.70999999999999996,"dosageForm":"","sponsorNew":"OSE Immunotherapeutics SA \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"OSE Immunotherapeutics SA \/ AbbVie Inc"},{"orgOrder":0,"company":"Kumquat Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","upfrontCash":"$130.0 million","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Kumquat Biosciences","amount2":1.3300000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":1.3300000000000001,"dosageForm":"","sponsorNew":"Kumquat Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Kumquat Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$150.0 million","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"IGM Biosciences","amount2":6.1699999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":6.1699999999999999,"dosageForm":"","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Large molecule","date":"April 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Antion Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"miCAR19","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Antion Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Antion Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Antion Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Immunology","country":"","productType":"Small molecule","date":"June 2024","year":"2024","type":"Funding","leadProduct":"7HP935","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"4","companyTruncated":"7 Hills Pharma \/ CPRIT"}]

    Find Novel Immunology Drugs in Preclinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cue Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Cue Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CUE-401

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Oppenheimer & Co

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cue Biopharma Announces Pricing of $12.0 Million Public Offering

                            Details : The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.

                            Brand Name : CUE-401

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 26, 2024

                            Lead Product(s) : CUE-401

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Oppenheimer & Co

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cue Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Cue Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CUE-401

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Oppenheimer & Co

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cue Biopharma Announces Proposed Public Offering

                            Details : The proceeds will advance the clinical development of company's autoimmune programs, including CUE-401, a bispecific fusion protein designed to induce and expand regulatory T cells, and CUE-501.

                            Brand Name : CUE-401

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 26, 2024

                            Lead Product(s) : CUE-401

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Oppenheimer & Co

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EydisBio

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            EydisBio

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor in Systemic Sclerosis

                            Details : EYD-001 is a highly selective and potent, orally bioavailable TAK1 inhibitor, which is being evaluated for the treatment of patients with systemic sclerosis.

                            Brand Name : HS-276

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2024

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biotherapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Biotherapeutics

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LANCL-based Therapy

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : NImmune Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NImmune Biopharma Collaborates with BioTherapeutics For Precision Immunology Drugs

                            Details : NImmune will leverage BioTherapeutics’ computational and preclinical services to accelerate biomarker-driven development of its LANCL immunoregulatory drug pipeline.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 05, 2024

                            Lead Product(s) : LANCL-based Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : NImmune Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            EydisBio

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            EydisBio

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : National Institute of Health

                            Deal Size : $2.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            EydisBio Awarded $2.6M Grant to Advance TAK1 Inhibitor Program for Systemic Sclerosis

                            Details : The grant will be used to further support EydisBio's ongoing research into the efficacy of EYD-001, a TAK1 inhibitor in animal models of systemic sclerosis.

                            Brand Name : EYD-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : EYD-001

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute of Health

                            Deal Size : $2.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            DeepCure

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            DeepCure

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DC-9476

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : LIRMM

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            DeepCure Partners with Leeds Institute To Study DC-9476 in Rheumatoid Arthritis

                            Details : The collaboration will investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for Rheumatoid Arthritis.

                            Brand Name : DC-9476

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 19, 2024

                            Lead Product(s) : DC-9476

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : LIRMM

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Conduit Pharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Conduit Pharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Conduit Pharma Selects Initial Indications for Autoimmune Disorder Candidate

                            Details : AZD1656, a HK-4 glucokinase activator, is now being repurposed by Conduit for for the treatment of systemic lupus erythematosus (including lupus nephritis) and ANCA-associated vasculitis.

                            Brand Name : AZD1656

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : AZD1656

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Trethera

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Trethera

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Trethera Wins $2M NIH Grant for Pediatric Neurologic Disease Development

                            Details : The funding aims to support Trethera’s clinical stage and first-in-class drug, TRE-515 dCK inhibitor, which is being evaluated for the treatment of acute disseminated encephalomyelitis.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Small Business Innovation Research

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Belhaven Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Belhaven Biopharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Lovelace Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution in Canine Study

                            Details : Nasdepi (epinephrine) a small molecule, dry powder nasal formulation is currently being investigated for the treatment of patients with anaphylactic reactions due to severe allergies.

                            Brand Name : Nasdepi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 09, 2024

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Lovelace Biomedical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            7 Hills Pharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            7 Hills Pharma

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7HP935

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : CPRIT

                            Deal Size : $4.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            7 Hills Pharma Receives $4.7MM Grant for Cell/Gene Therapy Technology in the Clinic

                            Details : 7 Hills will advance 7HP935, the Company’s lead first-in-class small molecule to augment CGT, through a Phase I clinical trial.

                            Brand Name : 7HP935

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : 7HP935

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : CPRIT

                            Deal Size : $4.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth